Brokers Issue Forecasts for PMVP Q3 Earnings

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) – HC Wainwright issued their Q3 2026 EPS estimates for shares of PMV Pharmaceuticals in a report issued on Friday, September 4th. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.25) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for PMV Pharmaceuticals’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for PMV Pharmaceuticals’ Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($1.03) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.17) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.12) EPS and FY2027 earnings at ($0.61) EPS.

Several other brokerages also recently weighed in on PMVP. LADENBURG THALM/SH SH assumed coverage on PMV Pharmaceuticals in a research report on Wednesday, July 8th. They set a “buy” rating and a $3.00 price target on the stock. Oppenheimer lowered their target price on PMV Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Finally, Weiss Ratings raised PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, PMV Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $4.33.

PMV Pharmaceuticals Price Performance

NASDAQ PMVP opened at $1.34 on Wednesday. PMV Pharmaceuticals has a 1 year low of $1.02 and a 1 year high of $1.88. The company has a market capitalization of $71.63 million, a PE ratio of -0.94 and a beta of 1.37. The company has a fifty day moving average of $1.25 and a 200 day moving average of $1.30.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.05.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Eversept Partners LP purchased a new position in PMV Pharmaceuticals in the 1st quarter valued at about $2,912,000. Stonepine Capital Management LLC purchased a new stake in PMV Pharmaceuticals during the 2nd quarter worth approximately $718,355. BlackRock Inc. purchased a new stake in PMV Pharmaceuticals during the 2nd quarter worth approximately $1,233,000. Susquehanna International Group LLP acquired a new position in shares of PMV Pharmaceuticals during the second quarter valued at approximately $50,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of PMV Pharmaceuticals during the second quarter valued at approximately $269,000. Institutional investors and hedge funds own 90.20% of the company’s stock.

Key Headlines Impacting PMV Pharmaceuticals

Here are the key news stories impacting PMV Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $5.00 price target, implying substantial upside from PMVP’s recent trading level. The firm forecasts losses of $1.03 per share for fiscal 2026 and $0.61 per share for fiscal 2027, narrower than the current full-year consensus loss estimate of $1.38. Its quarterly projections also show losses declining from $0.25 per share in Q3 2026 to $0.12 per share in Q4 2027, suggesting improving earnings trends. Analysts Set PMV Pharmaceuticals Target Price at $4.33
• Positive Sentiment: PMV Pharmaceuticals appointed Philip Herman as chief commercial officer. The addition of a dedicated commercial leader may signal preparation for future product commercialization and could strengthen investor confidence in the company’s ability to execute if its pipeline advances. PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
• Neutral Sentiment: Despite the more optimistic outlook, PMV remains unprofitable, with analysts expecting continued quarterly and annual losses. The company’s small market capitalization and early-stage biotechnology profile also leave the stock highly sensitive to clinical, regulatory, financing, and commercialization developments.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.